Eagle Pharmaceuticals, Inc. (EGRX)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Eagle Pharmaceuticals, Inc. (EGRX) trades at $0.15 with AI Score 60/100 (Hold). Eagle Pharmaceuticals, Inc. Market cap: $1.95M, Sector: Healthcare.
Last analyzed: Mar 15, 2026Eagle Pharmaceuticals, Inc. (EGRX) Healthcare & Pipeline Overview
Eagle Pharmaceuticals, Inc. develops and commercializes specialty pharmaceutical products, focusing on central nervous system disorders, metabolic critical care, and oncology. With a portfolio of approved drugs like Ryanodex and Belrapzo, and a pipeline of novel candidates, Eagle operates in a competitive landscape of generic and specialty drug manufacturers.
Investment Thesis
Eagle Pharmaceuticals operates with a focus on specialty pharmaceuticals, particularly in niche markets like malignant hyperthermia and certain cancer treatments. The company's profitability, indicated by a profit margin of 11.3% and a gross margin of 70.0%, suggests efficient operations. Upcoming catalysts include the potential approval and commercialization of pipeline products such as PEMFEXY and EA-114. However, the company faces risks associated with regulatory approvals, competition from generic drug manufacturers, and the inherent uncertainty of clinical trial outcomes. With a beta of 1.03, the stock's volatility is similar to the market average. The company's P/E ratio of 0.12 may indicate undervaluation, but further analysis is needed to assess the sustainability of earnings.
Based on FMP financials and quantitative analysis
Key Highlights
- Profit margin of 11.3% indicates efficient operations within the specialty pharmaceutical sector.
- Gross margin of 70.0% reflects strong pricing power and cost management.
- P/E ratio of 0.12 suggests potential undervaluation relative to earnings.
- Beta of 1.03 indicates market-average volatility.
- Focus on niche markets like malignant hyperthermia and specific cancer treatments provides a degree of specialization.
Competitors & Peers
Strengths
- Specialized product portfolio in niche markets.
- Established commercial infrastructure.
- Strategic collaborations and licensing agreements.
- High gross margin indicating strong pricing power.
Weaknesses
- Reliance on a limited number of key products.
- Exposure to generic competition.
- Dependence on regulatory approvals for pipeline products.
- Small market cap compared to larger pharmaceutical companies.
Catalysts
- Upcoming: Potential regulatory approval of PEMFEXY for non-small cell lung cancer and mesothelioma.
- Upcoming: Advancement of EA-114 (fulvestrant) through clinical trials for HR+/HER- breast cancer.
- Ongoing: Commercialization efforts for existing products like Ryanodex and Belrapzo.
- Ongoing: Progress in the strategic collaboration with Tyme Technologies, Inc. for SM-88.
Risks
- Potential: Failure to obtain regulatory approvals for pipeline products.
- Potential: Generic competition eroding market share for existing products.
- Potential: Unsuccessful clinical trial outcomes for product candidates.
- Ongoing: Dependence on a limited number of key products.
- Ongoing: Volatility associated with trading on the OTC market.
Growth Opportunities
- Expansion of PEMFEXY: PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed, targets non-small cell lung cancer and mesothelioma. The global market for lung cancer therapeutics is projected to reach $38.5 billion by 2027. Approval and successful commercialization of PEMFEXY could significantly boost Eagle's revenue, offering a more convenient alternative to existing pemetrexed formulations.
- Advancement of EA-114: EA-114 (fulvestrant) is being developed for HR+/HER- breast cancer. The global breast cancer therapeutics market is expected to reach $30 billion by 2028. Successful clinical trials and regulatory approval of EA-114 could provide Eagle with a significant share of this market, addressing a substantial unmet need in breast cancer treatment.
- Commercialization of EP-4104: EP-4104, a dantrolene sodium formulation, is intended to treat organophosphate exposure. While the market size for this specific indication is smaller, the potential for government contracts and stockpiling could provide a steady revenue stream. The ongoing threat of chemical warfare and terrorism supports the need for effective countermeasures.
- Partnership with Combioxin, SA: The collaboration with Combioxin, SA for CAL02, an antitoxin agent for severe pneumonia, offers potential in addressing antibiotic resistance. The global pneumonia therapeutics market is projected to reach $4.5 billion by 2025. Successful development and commercialization of CAL02 could provide a novel treatment option for severe pneumonia, addressing a critical unmet need.
- Strategic Collaboration with Tyme Technologies, Inc.: The collaboration for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas represents a significant growth opportunity. Success in clinical trials and subsequent commercialization could lead to substantial revenue streams, addressing critical needs in oncology.
Opportunities
- Expansion of existing product lines into new markets.
- Acquisition or licensing of additional pharmaceutical products.
- Successful clinical trials and regulatory approvals for pipeline products.
- Strategic partnerships to expand geographic reach.
Threats
- Generic erosion of key products.
- Unsuccessful clinical trials for pipeline products.
- Increased competition from other pharmaceutical companies.
- Changes in regulatory requirements.
Competitive Advantages
- Proprietary drug formulations and intellectual property protection.
- Established relationships with healthcare providers and distributors.
- Specialized expertise in developing and commercializing niche pharmaceutical products.
- Strategic collaborations and licensing agreements that expand product reach.
About EGRX
Eagle Pharmaceuticals, Inc., incorporated in 2007 and headquartered in Woodcliff Lake, New Jersey, is a pharmaceutical company dedicated to developing and commercializing innovative products that address unmet medical needs. The company's primary focus lies in the areas of central nervous system (CNS) disorders, metabolic critical care, and oncology. Eagle's portfolio includes both proprietary products and generic formulations, with a strategic emphasis on developing differentiated products that offer improved efficacy, safety, or ease of administration. Eagle's key marketed products include Ryanodex, used for the treatment of malignant hyperthermia, and Belrapzo and Bendeka, indicated for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. The company also has a pipeline of product candidates in various stages of development, including EP-4104 for organophosphate exposure, PEMFEXY for non-small cell lung cancer and mesothelioma, EA-114 for HR+/HER- breast cancer, and Vasopressin injection for vasodilatory shock. Eagle has established strategic collaborations and licensing agreements with companies like Combioxin, SA and AOP Orphan Pharmaceuticals GmbH to expand its product portfolio and geographic reach. The company also collaborates with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer and high-risk metastatic sarcomas.
What They Do
- Develops and commercializes pharmaceutical products.
- Focuses on central nervous system (CNS) disorders.
- Addresses metabolic critical care needs.
- Develops oncology treatments.
- Offers Ryanodex for malignant hyperthermia.
- Provides Belrapzo and Bendeka for certain types of lymphoma and leukemia.
- Develops product candidates like PEMFEXY and EA-114.
Business Model
- Develops and obtains regulatory approval for pharmaceutical products.
- Manufactures and markets its own proprietary products.
- Establishes licensing and collaboration agreements to expand its product portfolio.
- Generates revenue through product sales and royalties from partnered products.
Industry Context
Eagle Pharmaceuticals operates within the competitive specialty and generic drug manufacturing industry. This sector is characterized by intense competition, stringent regulatory requirements, and the constant need for innovation. Key trends include the increasing demand for generic drugs, the rising cost of drug development, and the growing importance of biosimilars. Eagle competes with both large pharmaceutical companies and smaller generic drug manufacturers. The company's success depends on its ability to develop and commercialize differentiated products, navigate the complex regulatory landscape, and maintain a strong intellectual property position.
Key Customers
- Hospitals and healthcare providers.
- Oncologists and hematologists.
- Pharmacies and distributors.
- Patients requiring specialized treatments for CNS disorders, metabolic critical care, and cancer.
Financials
Chart & Info
Eagle Pharmaceuticals, Inc. (EGRX) stock price: $0.15 (+0.00, +0.00%)
Latest News
-
Earnings Scheduled For November 14, 2023
benzinga · Nov 14, 2023
-
Stocks That Hit 52-Week Lows On Thursday
benzinga · Oct 5, 2023
-
Stocks That Hit 52-Week Lows On Friday
benzinga · Sep 8, 2023
-
Stocks That Hit 52-Week Lows On Wednesday
benzinga · May 10, 2023
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EGRX.
Price Targets
Wall Street price target analysis for EGRX.
MoonshotScore
What does this score mean?
The MoonshotScore rates EGRX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Michael Graves
CEO
Michael Graves serves as the CEO of Eagle Pharmaceuticals, Inc. His background includes extensive experience in the pharmaceutical industry, with a focus on strategic leadership, product development, and commercialization. Prior to joining Eagle, Graves held various leadership positions at other pharmaceutical companies, where he was responsible for driving growth and innovation. His expertise spans across multiple therapeutic areas, including CNS disorders, oncology, and metabolic diseases.
Track Record: Under Michael Graves' leadership, Eagle Pharmaceuticals has focused on expanding its product portfolio through strategic collaborations and internal development programs. Key milestones include the advancement of pipeline products through clinical trials and the successful commercialization of new formulations. Graves has also overseen the company's efforts to navigate the complex regulatory landscape and maintain a competitive position in the market.
EGRX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Eagle Pharmaceuticals may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Trading on the OTC Other tier often implies a higher degree of risk compared to companies listed on major exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Lower trading volume can lead to price volatility.
- Higher bid-ask spreads can increase transaction costs.
- Potential for delisting or suspension of trading.
- Increased risk of fraud or manipulation.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Monitor news and press releases for any red flags.
- Consult with a financial advisor before investing.
- Understand the risks associated with OTC trading.
- Established history of operations since 2007.
- Focus on developing and commercializing pharmaceutical products.
- Strategic collaborations with other pharmaceutical companies.
- Presence of a CEO and management team.
- Development of products addressing unmet medical needs.
EGRX Healthcare Stock FAQ
What does Eagle Pharmaceuticals, Inc. do?
Eagle Pharmaceuticals, Inc. is a pharmaceutical company that focuses on developing and commercializing specialty pharmaceutical products. Their primary focus is on treatments for central nervous system disorders, metabolic critical care, and oncology. The company both develops its own proprietary products and enters into licensing agreements to expand its portfolio, aiming to address unmet medical needs with differentiated pharmaceutical solutions.
What do analysts say about EGRX stock?
Analyst coverage of Eagle Pharmaceuticals, Inc. (EGRX) is limited due to its OTC listing and smaller market capitalization. Key valuation metrics, such as the P/E ratio of 0.12, may suggest potential undervaluation, but should be interpreted cautiously. Growth considerations revolve around the successful development and commercialization of pipeline products and the ability to maintain market share in the face of generic competition. Analyst consensus is pending updated stock data.
What are the main risks for EGRX?
The main risks for Eagle Pharmaceuticals, Inc. include the potential for failure to obtain regulatory approvals for its pipeline products, which could significantly impact future revenue streams. Generic competition poses a threat to existing products, potentially eroding market share and profitability. Additionally, unsuccessful clinical trial outcomes could delay or halt the development of key product candidates. Trading on the OTC market introduces additional risks related to liquidity and transparency.
What are the key factors to evaluate for EGRX?
Eagle Pharmaceuticals, Inc. (EGRX) currently holds an AI score of 60/100, indicating moderate score. Key strength: Specialized product portfolio in niche markets.. Primary risk to monitor: Potential: Failure to obtain regulatory approvals for pipeline products.. This is not financial advice.
How frequently does EGRX data refresh on this page?
EGRX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven EGRX's recent stock price performance?
Recent price movement in Eagle Pharmaceuticals, Inc. (EGRX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized product portfolio in niche markets.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider EGRX overvalued or undervalued right now?
Determining whether Eagle Pharmaceuticals, Inc. (EGRX) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying EGRX?
Before investing in Eagle Pharmaceuticals, Inc. (EGRX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Stock data pending update.
- OTC market data may have limited availability and reliability.